Lung cancer screening intervals based on cancer risk

被引:4
|
作者
Zhang, Li [1 ,2 ]
Yip, Rowena [2 ]
Jirapatnakul, Artit [2 ]
Li, Meng [1 ,2 ]
Cai, Qiang [2 ,3 ]
Henschke, Claudia, I [2 ,4 ]
Yankelevitz, David F. [2 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Dept Diagnost Radiol, Natl Canc Ctr, Natl Clin Res Ctr,Canc Canc Hosp, Beijing 100021, Peoples R China
[2] Icahn Sch Med Mt Sinai, Dept Radiol, New York, NY 10029 USA
[3] Shanxi Prov Peoples Hosp, Dept Radiol, Taiyuan 030012, Shanxi, Peoples R China
[4] Vet Adm Hlth Care Syst, Phoenix, AZ USA
关键词
Volume doubling time; Tumor aggressiveness; Risk prediction model; CT screening; PULMONARY NODULES; CT; TRIAL; MORTALITY; PROBABILITY; BENEFITS;
D O I
10.1016/j.lungcan.2020.09.013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: As low-dose CT screening is gaining acceptance, focus is on increasing the efficiency of screening. One major consideration is to reduce the total number of annual rounds by increasing the interval between screening rounds. It has been suggested that longer intervals could be used for individuals who are at lower risk of lung cancer. In this study, we explored whether eligible participants in a program of LDCT screening who are at lower risk of lung cancer have less aggressive cancers than those at higher risk. Methods: We retrospectively identified 118 participants in I-ELCAP database between 1992-2019 who had been screened using HIPAA-compliant protocols and had solid lung cancers diagnosed on an annual round of screening, 7-18 months after the prior round. Volume doubling time (VDT) for each cancer was calculated. Estimated risk of developing lung cancer was calculated using PLCOM2012 model. The strength of the relationship between VDT and individual PLCOM2012 scores was assessed by Pearson(r) and Spearman (rho) correlation coefficients. Results: VDTs were significantly different by cell-type (p < 0.0001); median VDT for small cell was 34.0 days, followed by other cell-types (61.8 days), squamous-cell (73.3 days), and adenocarcinoma (135.7 days). The median VDT for the 78 (66.1 %) Stage I lung cancers was significantly longer than the 40 Stage II + lung cancers (101.4 days vs. 45.5 days, p < 0.0001). None of the established lung cancer risk indicators (age, pack-years of smoking, or PLCOM2012 scores) were significant predictors of VDT or lung cancer stage. Conclusion: No significant relationship was demonstrated between risk of developing lung cancer (measured by risk models, age or smoking history) and lung cancer aggressiveness (measured by VDT, cell-type and Stage). This suggests that there is no evidence for determining intervals between repeat screenings using risk-based characteristics. It does not, however, exclude the possibility that future models may establish such a relationship.
引用
收藏
页码:113 / 119
页数:7
相关论文
共 50 条
  • [41] Personalised and risk based cancer screening
    Autier, Philippe
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2019, 367
  • [42] Factors influencing the intention for lung cancer screening in high-risk populations for lung cancer
    Cho, Mi-Kyoung
    Cho, Yoon Hee
    [J]. ASIA-PACIFIC JOURNAL OF ONCOLOGY NURSING, 2024, 11 (01)
  • [43] Evaluation Of Lung Cancer Risk Prediction Models For Selecting Smokers For CT Lung Cancer Screening
    Katki, H.
    Kovalchik, S.
    Petito, L.
    Cheung, L. C.
    Jacobs, E.
    Jemal, A.
    Berg, C.
    Chaturvedi, A.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [44] Genetic Risk Score (GRS) and Lung Cancer Biology Affect Lung Cancer Screening Outcomes
    Young, R. P.
    Scott, R. J.
    Silvestri, G. A.
    Gamble, G. D.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [45] Lung cancer screening an asbestos exposed population: Existing lung cancer risk criteria are not sufficient
    Brims, Fraser J. H.
    Harris, Edward J. A.
    Murray, Conor
    Kumarasamy, Chellan
    Ho, Alice
    Adler, Brendan
    Franklin, Peter
    de Klerk, Nick H.
    [J]. RESPIROLOGY, 2023, 28 (06) : 543 - 550
  • [46] Risk of Second Lung Cancer in ITALUNG LDCT Screening
    Mascalchi, Mario
    Sali, Lapo
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (06) : E105 - E106
  • [47] Lung cancer screening: identifying the high risk cohort
    Marcus, Michael W.
    Raji, Olaide Y.
    Field, John K.
    [J]. JOURNAL OF THORACIC DISEASE, 2015, 7 : S156 - S162
  • [48] The real risk of lung cancer screening is failure to operate
    Wright, Gavin
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 63 - 63
  • [49] Evaluation of cardiovascular risk in a lung cancer screening cohort
    Ruparel, Mamta
    Quaife, Samantha L.
    Dickson, Jennifer L.
    Horst, Carolyn
    Burke, Stephen
    Taylor, Magali
    Ahmed, Asia
    Shaw, Penny
    Soo, May-Jan
    Nair, Arjun
    Devaraj, Anand
    O'Dowd, Emma Louise
    Bhowmik, Angshu
    Navani, Neal
    Sennett, Karen
    Duffy, Stephen W.
    Baldwin, David R.
    Sofat, Reecha
    Patel, Riyaz S.
    Hingorani, Aroon
    Janes, Sam M.
    [J]. THORAX, 2019, 74 (12) : 1140 - 1146
  • [50] Lung cancer screening and its continuous risk assessment
    de Koning, Harry J.
    [J]. LANCET ONCOLOGY, 2017, 18 (11): : 1434 - 1436